Designing the next-generation clinical care pathway for Alzheimer’s disease

Harald Hampel, Rhoda Au, Soeren Mattke, Wiesje M. van der Flier, Paul Aisen, Liana Apostolova, Christopher Chen, Min Cho, Susan de Santi, Peng Gao, Atsushi Iwata, Ricky Kurzman, Andrew J. Saykin, Stefan Teipel, Bruno Vellas, Andrea Vergallo, Huali Wang, Jeffrey Cummings

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)


The reconceptualization of Alzheimer’s disease (AD) as a clinical and biological construct has facilitated the development of biomarker-guided, pathway-based targeted therapies, many of which have reached late-stage development with the near-term potential to enter global clinical practice. These medical advances mark an unprecedented paradigm shift and requires an optimized global framework for clinical care pathways for AD. In this Perspective, we describe the blueprint for transitioning from the current, clinical symptom-focused and inherently late-stage diagnosis and management of AD to the next-generation pathway that incorporates biomarker-guided and digitally facilitated decision-making algorithms for risk stratification, early detection, timely diagnosis, and preventative or therapeutic interventions. We address critical and high-priority challenges, propose evidence-based strategic solutions, and emphasize that the perspectives of affected individuals and care partners need to be considered and integrated.
Original languageEnglish
Pages (from-to)692-703
Number of pages12
JournalNature Aging
Issue number8
Publication statusPublished - 1 Aug 2022

Cite this